Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opening Session Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Feb
19
Today In Oncology
Genetics Pioneer Zsofia Stadler to Lead JCO Precision Oncology
Does Diabetes Increase Pancreatic Cystic Neoplasm Risk
Topline PFS Results From BREAKWATER in mCRC Newly Announced
Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer
Pleurectomy Decortication Safe in Select Patients With Pleural Mesothelioma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo